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Transdifferentiation of fibroblasts into induced
neuronal cells (iNs) by the neuron-specific tran-
scription factors Brn2, Myt1l, and Ascl1 is a para-
digmatic example of inter-lineage conversion
across epigenetically distant cells. Despite tremen-
dous progress regarding the transcriptional hierar-
chy underlying transdifferentiation, the enablers of
the concomitant epigenome resetting remain to
be elucidated. Here, we investigated the role of
KMT2A and KMT2B, two histone H3 lysine 4 meth-
ylases with cardinal roles in development, through
individual and combined inactivation. We found
that Kmt2b, whose human homolog’s mutations
cause dystonia, is selectively required for iN
conversion through suppression of the alternative
myocyte program and induction of neuronal
maturation genes. The identification of KMT2B-
vulnerable targets allowed us, in turn, to expose,
in a cohort of 225 patients, 45 unique variants in
39 KMT2B targets, which represent promising
candidates to dissect the molecular bases of
dystonia.988 Cell Reports 25, 988–1001, October 23, 2018 ª 2018 The Author
This is an open access article under the CC BY-NC-ND license (http://INTRODUCTION
The conversion of murine embryonic fibroblasts (MEFs) into
induced neuronal cells (iNs) through forced expression of the
Brn2, Ascl1, and Myt1l transcription factors (TFs) (hereafter
called BAM [Brn2, Ascl1, Mytl1] factors) defined the paradigm
of transdifferentiation across germ layers (Vierbuchen et al.,
2010). BAM factors synergistically cooperate in this process
(20% efficiency), which does not require either proliferation
or the transient reacquisition of pluripotency (Vierbuchen et al.,
2010). ASCL1 instructs transdifferentiation as a pioneer TF,
recognizing trivalent chromatin states marked by H3
lysine 4 monomethylation (H3K4me1), lysine 9 trimethylation
(H3K9me3), and lysine 27 acetylation (H3K27ac) (Wapinski
et al., 2013). BRN2 and MYT1L are, instead, critical for iN matu-
ration and the suppression of alternative cell fates; upon Ascl1-
only infection, MEFs that fail to become iNs deviate toward
myocytes, an outcome that is prevented by co-transduction
with Brn2 andMyt1l (Mall et al., 2017; Treutlein et al., 2016; Wa-
pinski et al., 2013).
ASCL1 has been recently shown to effect massive remodeling
of chromatin accessibility and nucleosome phasing, with open
chromatin loci enriched for neuronal and muscle pathway
genes (Wapinski et al., 2017). Moreover, MEF-to-iN conversion
features amajor chromatin reconfiguration in the first 5 days after
Ascl1 induction, following which further chromatin transitionss.
creativecommons.org/licenses/by-nc-nd/4.0/).
represent less than 20% of all changes underlying direct
neuronal conversion (Wapinski et al., 2017). This suggests that
these epigenetic transitions are not as gradual as during reprog-
ramming to pluripotency (Cacchiarelli et al., 2015; Chronis et al.,
2017), but the role of specific chromatin regulators in these
accompanying waves of chromatin resetting remains elusive.
Here, we investigated the roles of KMT2A and KMT2B in
MEF-to-iN conversion in light of their critical function in lineage
decisions. KMT2A and KMT2B belong to Set1-Trithorax type
H3K4 methylases, specifically responsible for the deposition of
histone H3 lysine 4 trimethylation (H3K4me3) at gene promoters
(Denissov et al., 2014).
Both associate with MENIN, which mediates their localization
at specific loci, such as HOX genes (Glaser et al., 2006; Hughes
et al., 2004; Lee et al., 2006). Despite their high homology,
KMT2A and KMT2B are spatially and temporally non-redundant.
Thus, knockout (KO) of either Kmt2a (Ernst et al., 2004) or Kmt2b
(Glaser et al., 2006) is embryonic lethal at embryonic day 12.5
(E12.5) or E.10.5, respectively. Furthermore, KMT2A and
KMT2B have specific roles during mammalian neuronal differen-
tiation. During retinoic acid-based differentiation, the two
enzymes regulate different HOX genes (Denissov et al., 2014),
and Kmt2b/ embryonic stem cells (ESCs) show a severe delay
in in vitro differentiation toward the ectodermal lineage (Lubitz
et al., 2007). Adult neurogenesis and function are also specif-
ically affected. Indeed, Kmt2a/ subventricular zone neural
stem cells (SVZ NSCs) are impaired selectively in neuronal differ-
entiation, whereas both KMT2A and KMT2B contribute to
memory formation, albeit through distinct target pathways and
with no apparent effects on brain and neuronal morphology
(Kerimoglu et al., 2013, 2017; Lim et al., 2009). Finally, mutations
in KMT2A and KMT2B cause two distinct brain disorders:
Wiedemann-Steiner syndrome, featuring intellectual disability,
and a newly recognizedmolecular subset of early-onset general-
ized dystonia, respectively (Meyer et al., 2017; Strom et al., 2014;
Zech et al., 2016).
RESULTS
Conditional Inactivation of Kmt2a and Kmt2b upon
Transdifferentiation
To study the role of KMT2A and KMT2B during transdifferentia-
tion, we employed conditional mouse strains carrying exon 2 of
Kmt2a and/or Kmt2b flanked by LoxP sites, the knockin of the
YFP-coding gene into one Rosa26 allele downstream of a
LoxP-flanked transcription termination cassette (STOP
cassette), and the gene coding for the tamoxifen-inducible
version of Cre recombinase knocked into the second Rosa26
allele (Glaser et al., 2006; Kranz et al., 2010; Testa et al., 2004).
Upon 4-hydroxytamoxifen (4-OHT) administration, Cre is ex-
pressed, generating a frameshift mutation in Kmt2a and/or
Kmt2b (Figure 1A). MEFs were derived from Kmt2a (and/or
Kmt2b)fl/fl Cre+ YFP+ embryos and from Kmt2a+/+Kmt2b+/+
Cre+ YFP+ or Kmt2afl/+ Cre+ YFP+ for Kmt2a conditional KO
(cKO) as controls (Figure 1A). After 5 days of 4-OHT treatment
followed by either 2 or 7 days in normal medium (Figure 1B),
depletion of Kmt2a and/or Kmt2b was assessed by qRT-PCR
(Figure 1C) and western blot (Figure 1D).Transdifferentiation was then implemented according to the
original protocol (Vierbuchen et al., 2010; Figure 1B). The sus-
tained expression of YFP (Figure S1A) along with permanent
loss of Kmt2b exon 2 (Figure S1B) through the end of transdiffer-
entiation excluded selection of Kmt2bfl/fl iNs that might have
escaped recombination.
To decipher the role of the two KMT2 methylases, we
integrated two complementary approaches to capture the
acquisition of iN identity along transdifferentiation: morpholog-
ical analysis through an automated and unbiased imaging
method (ScanR) and cytofluorimetric analysis (fluorescence-
activated cell sorting [FACS]) for the expression of polysialic
acid-neural cell adhesion molecule (PSA-NCAM), a marker of
iN induction (Figure 1B). Transcriptomic and epigenomic
profiling was then performed at 5 and 13 days of transdifferentia-
tion (Figure 1B). Day 5 was chosen as reference starting point
because, at this time, MEFs are still equally competent to
become iNs, having all undergone convergent transcriptional
changes (Treutlein et al., 2016). Day 13 was selected as the
endpoint because 8 days following transduction no more iNs
are induced, and the 13-day iNs have been shown to be func-
tionally mature (Vierbuchen et al., 2010). MEFs were also profiled
at the epigenomic level at the onset of transdifferentiation to
define their initial chromatin configuration (Figure 1B).
Kmt2b Ablation Impairs Transdifferentiation
We evaluated the transdifferentiation potential of Kmt2a/ and/
or Kmt2b/ MEFs in terms of both efficiency of iN generation
and degree of their maturation. To distinguish between the effect
of their loss on cell mortality and transdifferentiation, we har-
nessed the observation that already 1 day after doxycycline
administration (day 3), the vast majority of cells are post-mitotic
(Vierbuchen et al., 2010). To confidently ascribe any change in
cell number to cell mortality rather than to cell proliferation, we
selected cKO and control samples starting transdifferentiation
from the empirically validated same number of cells on day 3.
We found that loss of Kmt2b greatly impaired transdifferentia-
tion efficiency in a manner independent of the mortality rate that
accompanies transdifferentiation (Figures 2A and 2B; Table S1).
In contrast, for the loss of Kmt2a, transdifferentiation efficiency
was correlated with cell viability (Figures S1C and S1D; Table
S1), pointing to the former as a by-product of the latter.
Next we sought to determine whether there is any redundancy
between the two methylases by knocking out both enzymes.
Kmt2a/Kmt2b/ transdifferentiated MEFs showed both the
highest cell death and the lowest conversion efficiency, indi-
cating that KMT2A only partially compensates for the lack of
KMT2B during transdifferentiation (Figures 2A and 2B; Table
S1). Importantly, the combined loss of Kmt2a and Kmt2b did
not affect MEF viability per se but was specifically triggered
upon induction of transdifferentiation (Figures S1E and S1F).
We confirmed these observations through FACS-based
quantitation of PSA-NCAM+ cells. Indeed, both Kmt2a/ and
Kmt2b/ MEFs showed a lower efficiency of iN induction with
respect to controls (Figure 2C), but although, for Kmt2a/
MEFs, this was entirely accounted for by the higher rate of cell
death (Figures 2D, S1G and S1H), for Kmt2b/ MEFs, it was
independent of cell death and, thus, imputable to a specificCell Reports 25, 988–1001, October 23, 2018 989
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Figure 1. Experimental System
(A) Schematic of Kmt2 cKO MEF derivation and 4-OHT treatment.
(B) Schematic of our experimental pipeline.
(C) Representative qPCR results for exon 2 copy number after 4-OHT treatment. Means ± SEM.
(D)Western blot analysis for KMT2B, with VINCULIN (VCL) as housekeeping, of MEFs treated 5 days with 4-OHT and left 7 days in culture without 4-OHT. The first
lane was dedicated to ESCs.
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requirement for KMT2B in transdifferentiation (Figures 2D, S1I
and S1J). Moreover, although cell mortality in Kmt2a/ transdif-
ferentiating MEFs was higher with respect to Kmt2b/ and
controls (Figure 2D), the percentage of Kmt2a/ PSA-NCAM+
cells overlapped or was even higher than in controls along the
entire process (Figure 2E). This indicates that PSA-NCAM+ and
PSA-NCAM fractions are at least equally vulnerable to cell
death across Kmt2a/ and Kmt2a+/+.
Finally, FACS analysis of the combined KO showed that,
although the viability ofKmt2a/Kmt2b/MEFswas compara-
ble with that of Kmt2a/ and lower than that of controls (Figures
2D, S1K and S1L), their transdifferentiation efficiency was
strongly reduced with respect both to control and the single
cKO transdifferentiating MEFs (Figure 2C), underscoring that
KMT2B is the main H3K4 trimethylase involved in direct cell
conversion.
Then we analyzed the morphology of the generated iNs to
probe the role of either methylase on iN maturation. To this
aim, we investigated neurite elongation as a defining hallmark
of complete iN conversion, finding that, in Kmt2b/ iNs, it was
severely reduced both at 13 (Figures 2F, 2I, S2A, and S2B) and
21 days (Figure 2G) of transdifferentiation. On the contrary,
and consistent with the unaltered efficiency of iN conversion,
neurite length in Kmt2a/ iNs was fully comparable with that
of Kmt2a+/ (Figures 2F, 2G, 2H, S2C, and S2D). Finally, the
few double cKO iNs only showed minimal neurite elongation
(Figures 2F, 2J, and S2E). This demonstrates that KMT2B, be-
sides playing a fundamental role in MEF-to-iN conversion, has
also a specific effect on iN maturation.
KMT2B Controls Transcriptome Resetting in MEF-to-iN
Conversion
Given the role of KMT2B in H3K4me3 deposition at promoters
(Denissov et al., 2014), its loss could impair the gene expression
program underlying MEF-to-iN transition. To unveil the molecu-
lar basis of the dual phenotype observed upon loss of KMT2B
(namely, less efficient iN conversion and defective iN matura-
tion), we performed RNA sequencing (RNA-seq) on sorted
PSA-NCAM+ and PSA-NCAM Kmt2b/ and control cells at
day 13 of transdifferentiation. In particular, through the analysis
of PSA-NCAM+ transcriptomes, we aimed to establish whichFigure 2. KMT2B Is Essential for MEF-to-iN Transition
(A) Efficiency of transdifferentiation in ScanR experiments, calculated relating, for a
3 days after plating.
(B) Cell mortality in ScanR experiments, calculated as the ratio of DAPI 3 days (D
(A and B) Kmt2a+/+Kmt2b+/+, n = 3; Kmt2bfl/fl, n = 2; Kmt2afl/flKmt2bfl/fl, n = 1.
(C) Efficiency of transdifferentiation in FACS experiments, calculated relating the
(D) Percentage of dead cells, calculated at 13 days, over the initial number of pla
(C and D) The number of independent embryos per genotype corresponds to the
(E) Percentage of PSA-NCAM+ cells among transdifferentiating MEFs 5, 7, 9, 13
pendent embryos per time point per genotype is reported under the graph.
(F) Representative images of three different experiments, each reporting the spec
right), Kmt2a/ (bottom left), Kmt2b/ (bottom center), and Kmt2a/Kmt2b/
(G) Representative images of 21-day Kmt2a+/+Kmt2b+/+ (left), Kmt2a/ (center),
(H–J) Average neurite length per neuron, calculated with Neuritetracer on day 1
Kmt2a/ Kmt2b/ iNs (J) were compared to controls.
In the case of Kmt2a ScanR experiments (F and H),Kmt2afl/MEFswere used as a
4-OHT, whereas, in (A)–(E), (G), and (I), MEFs were plated 7 days after 4-OHT. (A
992 Cell Reports 25, 988–1001, October 23, 2018genes responsible for transdifferentiation were differentially ex-
pressed in the absence of KMT2B and how Kmt2b/ iNs
differed from controls. Instead, through PSA-NCAM transcrip-
tomic profiling, we pursued mechanistic insight into the effect
of Kmt2b loss on MEF-to-iN conversion.
The first component identified by principal-component anal-
ysis (PCA) clearly distinguished genotypes in both PSA-NCAM
populations (Figures S3A and S3B), indicating that Kmt2b status
represents the largest source of variation in the datasets. Specif-
ically, through the analysis of PSA-NCAM+ cells, we found 1,508
differentially expressed genes (DEGs) between Kmt2b/ and
control iNs (at false discovery rate [FDR] < 0.01 and with at least
a 50% fold change), the majority of which were downregulated in
the latter, consistent with the gene-activating function of KMT2B
(Figure 3A). To define which stage of transdifferentiation was
most affected by loss of KMT2B, we clustered day 13 DEGs be-
tween Kmt2b/ and control iNs using K-means clustering
according to their established expression pattern throughout
transdifferentiation (Wapinski et al., 2013; Figure 3B). Genes
that are normally expressed on day 15 and downregulated on
day 24 of transdifferentiation (clusters 2 and 3) were found to
be already lowly expressed at 13 days in our Kmt2b/ samples,
further highlighting a defectiveMEF-to-iN transition. On the other
hand, a high proportion of cluster 4, whose expression gradually
increases throughout transdifferentiation, peaking at day 24, and
that is enriched for synaptic genes and RE1-silencing transcrip-
tion factor (REST) targets (4.79-fold enrichment, q-value [q]
 1e54 in neuronal progenitors), was downregulated in
Kmt2b/ iNs, further corroborating the defective neuronal fate
acquisition in the absence of KMT2B.
Recently, Treutlein et al. (2016) integrated the single-cell tran-
scriptomes of Ascl1-only infected MEFs throughout transdiffer-
entiation with those of 15-day BAM-infected iNs and identified
the transcriptional regulators that most likely coordinate transdif-
ferentiation progression, defining three subnetworks (i.e., MEF,
initiation and maturation). We found that, in our PSA-NCAM+
dataset, the most disrupted subnetwork by loss of KMT2B was
the maturation one, confirming at the molecular level the defec-
tive iN maturation phenotype we observed (Figure 3C). Indeed,
the top 30 DEGs (Figures 3A and S3C) that have annotated
function(s) included four key promoters of physiological neuriteny chosen concentration, the number of Tuj1+ at 13 days to the number of DAPI
API start) and 13 days (DAPI end) after plating.
number of PSA-NCAM+ cells at 13 days to the number of plated cells.
ted MEFs.
one reported for time point 13 days of (E).
, and 21 days after plating, assayed with FACS analysis. The number of inde-
ific cKO and its control. Kmt2afl/ (top left), Kmt2a+/+Kmt2b+/+ (top, center and
(bottom right) iNs at 13 days are reported (DAPI in blue and Tuj1 in red).
and Kmt2b/ (right) iNs acquired with the bright-field microscope.
3 of transdifferentiation. In particular Kmt2a/ iNs (H), Kmt2b/ iNs (I), and
control. In (F), (H), and (J), MEFs were plated for BAM transduction 2 days after
)–(E) and (H)–(J), means ± SEM; ***p < 0.0001; *p < 0.01; ns, not significant.
(legend on next page)
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Figure 4. Early Dysregulation of MEF-to-iN Conversion in the Absence of KMT2B
(A) Correlation of fold changes in Kmt2b/ across PSA-NCAM and PSA-NCAM+ cells. All tested genes are plotted.
(B) Heatmap of expression across normal transdifferentiation (left) and on day 13 (right) of DEGs with genome-wide significance in both cell fractions and also
significantly differentially expressed during normal transdifferentiation. Z scores were calculated separately for the left and right portions of the heatmap.extension (Ppp1r9a,Myo16, Lrfn1, and Prka1b) and nine regula-
tors of synapse formation, maturation, and function (Clstn3,
Jph4, Syp, Sult4a1, Ptprn, Cadm3, Adcy1, Grin2b, and Ache).
Together, these results show that the defective iN phenotype
observed upon loss of KMT2B is determined by dysregulation
of the transcriptional program sustaining iN maturation.
To gain deeper insight into this phenomenon, we next
compared the transcriptomes of our 13-day iNswith those of sin-
gle cells undergoing MEF-to-iN transition (Treutlein et al., 2016).
Strikingly, Kmt2b/ PSA-NCAM+ iNs showed a higher correla-
tion with the transcriptomes of earlier stages of transdifferentia-
tion, providing the molecular basis for our observation that the
few Kmt2b/ MEFs that manage to convert to iNs fail to un-
dergo complete neuronal maturation (Figures S3D and S3E).
Furthermore, these maturation-defective iNs also present an
increased correlation with myocyte gene expression, suggesting
a concomitant failure to fully suppress alternative fates (Figures
S3D and S3E). Thus, to confirm whether Kmt2b/MEFs, which
transdifferentiated less efficiently than controls, switched toward
the myocyte fate, we compared Kmt2b/ and control PSA-
NCAM 13-day transcriptomes and found that upregulated
genes in Kmt2b/ PSA-NCAM cells were significantly en-
riched for targets bound by ASCL1 in the first phases of transdif-
ferentiation (Wapinski et al., 2013; Figure 3D). Although these
ASCL1-bound genes have been identified in MEFs transduced
either with this TF alone (3.9-fold, p  2e7) or with all BAM fac-
tors (3-fold, p 2e10), a large fraction is then rapidly repressedFigure 3. KMT2B Loss Impairs Transcriptomic Changes Underlying Tr
(A) Volcano plot highlighting the top DEGs among Kmt2b/ and control 13-day
(B) DEGs upon Kmt2b KO clustered on the basis of their expression pattern ac
kilobase pair per million reads sequenced [FPKM], scaled across the whole data
(C) Heatmap showing the expression across genotypes in iNs sorted at 13 days of
Treutlein et al. (2016). The significant DEGs betweenKmt2b/ and the control are
MEFs were derived.
(D) Expression pattern during normal transdifferentiation (right) and across genoty
(E) GO enrichment analysis of genes upregulated in 13-day Kmt2b/ PSA-NCA
(F) MyoD1 normalized counts in control and Kmt2b/ PSA-NCAM cells. Mean
994 Cell Reports 25, 988–1001, October 23, 2018by BRN2 andMYT1L in BAM-transducedMEFs (Figure 3D), pre-
venting the shift toward myocytes (Treutlein et al., 2016). There-
fore, the enrichment for such genes in Kmt2b/ PSA-NCAM
cells indicates that loss of KMT2B prevents their expected
silencing, rerouting conversion toward alternative fates.
Consistent with this observation, the top gene ontology (GO)
enrichments of upregulated genes in Kmt2b/ PSA-NCAM
cells were all related to myocyte fate acquisition and function
(Figure 3E). Moreover, among these genes, we scored a
35-fold increase in MyoD1, a fundamental driver of myogenic
differentiation (Pinney et al., 1988; Figure 3F).
Because we observed a very high correlation in fold
changes between the transcriptomes (correlation [cor]  0.8,
p  2e16) of PSA-NCAM+ and PSA-NCAM fractions
(Figure 4A), we hypothesized that much of the impairment in
Kmt2b/ transcriptomic resetting occurred early during MEF-
to-iN transition. Thus, we analyzed the genes that changed in
the same direction in both PSA-NCAM fractions and whose
level of expression is regulated during transdifferentiation (Wa-
pinski et al., 2013). Indeed, most of the genes downregulated in
the absence of KMT2B in both fractions are upregulated in the
first phases of transdifferentiation (Figure 4B), and among
them, we found the genes of the maturation subnetwork,
Zfp612, Arnt2, and Lass4. In particular, Arnt2 and Zfp612 are
upregulated or remain expressed only when MEFs are trans-
duced with either Brn2 or Myt1l or all BAM factors but not
with Ascl1 alone. Hence, in the absence of KMT2B, theseansdifferentiation
iNs.
ross stages of transdifferentiation (plotted are log-normalized fragments per
set).
the transcriptional regulators belonging to the three subnetworks described by
indicated by red arrows. Each line represents a different embryo fromwhich the
pes on day 13 (left) of the DEGs found in 13-day Kmt2b/ PSA-NCAM cells.
M cells with respect to controls.
s ± SD are reported. *, FDR < 0.01.
Figure 5. The Histone Methylation Patterns of Kmt2b/ MEFs Prefigure Gene Repression in Untransdifferentiated cKO Cells
(A) MEF H3K4me3 coverage (in reads per kilobase million [RPKM]) in Kmt2b/, control, and double-mutant MEFs 2 and 7 days after the last 4-OHT admin-
istration around the TSS of DEGs in Kmt2b/ and control transdifferentiating cells.
(B) MEF H3K4me3 RPKM around the TSS of genes downregulated in both PSA-NCAM fractions (left) and in Kmt2b/ PSA-NCAM+ cells only (right).
(C) H3K27me3 RPKM around the TSS of genes downregulated in Kmt2b/ PSA-NCAM cells, in MEFs, and at 5 days of transdifferentiation.genes could not be activated despite the presence of Brn2 and
Myt1l. Furthermore, one of the main direct targets of ASCL1,
the repressor ZFP238 (Wapinski et al., 2013), was deregulated
both in PSA-NCAM+ and PSA-NCAM Kmt2b/ fractions with
respect to controls (Figure 4B), underscoring that the loss of
KMT2B disrupts the dynamic interplay among BAM factors
on their targets.
Together, the combined transcriptomic analysis of PSA-
NCAM+ and PSA-NCAM cKO and control cells demonstrates
that, upon transdifferentiation, Kmt2b/MEFs undergo an early
massive dysregulation of the transcriptional program enabling
conversion. This, on one side, leads to a lower transdifferentia-
tion efficiency and a substantial shift toward a myocytic fate;
on the other, it prevents the few converting Kmt2b/ cells
from activating the full neuronal maturation program.Elucidation of the KMT2B-Vulnerable Epigenome
Next, we proceeded to analyze how the epigenome resetting un-
derliesMEF-to-iN conversion. To define howKMT2B loss affects
the balance between H3K4me3 and histone H3 lysine 27 trime-
thylation (H3K27me3) deposition at specific loci (Austenaa
et al., 2012), we performed chromatin immunoprecipitation
coupled to deep sequencing (ChIP-seq) on MEFs 2 and 7 days
after 4-OHT administration. We first observed that most of the
genes that were downregulated in both cell fractions (i.e., PSA-
NCAM+ and PSA-NCAM) were H3K4me3-marked in control
MEFs and lost this mark already 2 days after 4-OHT administra-
tion in Kmt2b/ MEFs (Figure 5A). The loss of KMT2B had,
instead, a milder effect, and on a smaller proportion of the tran-
scription start site (TSS), for the genes downregulated in
PSA-NCAM+ cells (Figures 5A and 5B). Moreover, the decreaseCell Reports 25, 988–1001, October 23, 2018 995
Figure 6. H3K4me3 Remodeling along
Neuronal Transdifferentiation and Differen-
tiation
(A) PCA across the union of H3K4me3 sites in
Kmt2b/ and control transdifferentiating MEFs at
5 and 13 days (in the latter after sorting for PSA-
NCAM) and in MEFs prior to transdifferentiation.
(B) Quilt of the GO enrichment analysis regarding
the cellular components of the genes both differ-
entially H3K4 trimethylated and expressed (FDR <
0.01, fold change [FC] > 0.5) in Kmt2b/ with
respect to the control.
(C) Correlation of fold change in 13-day Kmt2b/
iNs with fold change in Kmt2b/ hippocampal
neurons. Only genes significantly dysregulated in
both datasets are plotted.
(D) Distribution of fold changes in H3K4me3 in
in vivo Kmt2b/ hippocampal neurons (Kerimoglu
et al., 2017) of sites that lose H3K4me3 in trans-
differentiating Kmt2b/ versus control cells.
(E) Enrichments for biological processes among
genes with decereased H3K4me3 in BAM-treated
KO cells but not in CaMKII neurons, against the
background of all H3K4me3-marked genes.in H3K4me3 was accompanied by an increase in H3K27me3 at
these TSS, which, already in cKO MEFs before the onset of iN
conversion, had a magnitude comparable with the increase
observed at 5 days of transdifferentiation (Figure 5C). This
suggests that the epigenome remodeling, which rapidly follows
the loss of KMT2B, disfavors MEF-to-iN conversion and, more
specifically, that the initial failure of Kmt2b/ MEFs in keeping
active a specific subset of genes (Figure 5C) has a major, very
early effect on transdifferentiation efficiency, whereas the effect
of Kmt2b loss on neuronal maturation likely occurs at later steps.
Thus, to specifically dissect the epigenome resetting underly-
ing iN maturation, we performed ChIP-seq on control and
Kmt2b/ MEFs on days 5 and 13 of transdifferentiation, also
including the day 5 Kmt2a/ background.
The Kmt2a/ sample clustered together with controls in the
PCA, further demonstrating the lack of effect of the absence of
KMT2A on transdifferentiation (Figure 6A).
As expected by the ChIP-seq onMEFs, for the largest majority
of differentially marked regions, the loss of H3K4me3 was main-
tained from day 5 to day 13, whereas, for a small subset of loci,
the loss was reverted on day 13 (Figure S4A). The latter were996 Cell Reports 25, 988–1001, October 23, 2018particularly enriched for genes related to
the regulation of nervous system devel-
opment (2.4-fold enrichment, q  0.009)
and intracellular ligand-gated ion channel
activity (15-fold enrichment, q  0.007),
suggesting delayed compensation on a
subset of KMT2B targets enabling the
acquisition, albeit severely compro-
mised, of neuronal identity.
On the other hand, we identified 112
genes that presented lower H3K4me3 in
Kmt2b/ transdifferentiating MEFs
already on day 5 and that showed afurther decrease in the H3K4me3 level at 13 days. Among these,
47 were also downregulated in 13-day iNs (Figure S4B), indi-
cating that KMT2B is necessary for the maintenance of the
mark at these loci and for their sustained activation.
In light of the parallel changes in H3K4me3 on day 5 and 13 re-
vealed by the PCA, we analyzed all samples together, adjusting
for the differences linked to time points. Upon loss of Kmt2b, we
found 994 sites, mapping at the TSS of 545 genes, showing
decreased H3K4me3 and 95 sites, mapping at the TSS of 82
genes, presenting an increased H3K4me3. Among the 82 genes,
only Runx1t1 was differentially expressed in Kmt2b/ iNs with
respect to controls (Figure S4C).
We found that, of the 545 genes showing a reducedH3K4me3,
143 were significantly differentially expressed, underscoring the
critical importance of KMT2B-mediated H3K4me3 deposition as
a source of differential expression (overlap, p  2e59, hyper-
geometric test) while extending the observation that only
subsets of KMT2B-dependent H3K4me3 targets are transcrip-
tionally vulnerable (Hu et al., 2017). Some of the most
significantly enriched GO categories among these genes
were related to neuronal cell components (e.g., axon),
pointing to a KMT2B-mediated gene expression programwhose
disruption underlies defective iN specification and maturation
(Figure 6B).
Next, to investigate how the role of KMT2B in transdifferentia-
tion relates to the physiological maintenance of the neuronal
fate, we compared the transcriptomic and epigenomic data
of Kmt2b/ iNs with those of in vivo post-mitotic hippocam-
pal neurons (transcriptomes from whole hippocampi and
H3K4me3 profiles from hippocampal neurons, respectively), in
which Kmt2b loss was driven by Ca2+/calmodulin-dependent
protein kinase II (CaMKII)-dependent Cre expression (Kerimoglu
et al., 2017).We observed that the 116DEGs shared between the
two datasets were dysregulated in the same direction (cor
p  9e7) (Figure 6C). Indeed, of the sites that lost H3K4me3
in our BAM-treated cKO cells, about 90% were detectable in
some of the in vivo samples, and of these, 80% also showed a
reduction in H3K4me3 in Kmt2b/ hippocampal neurons (Fig-
ure 6D). Thus, loss of Kmt2b affects a core set of sites that
lose H3K4me3 independently of the stage of neuronal determi-
nation, pointing to a fundamental convergence between the pro-
cesses of iN conversion and the maintenance of physiologically
acquired neuronal fate. Instead, the genes that lost themark only
in the transdifferentiation paradigm presented an enrichment for
positive regulation of both neurogenesis and cell projection or-
ganization, concordant with the specific features of our impaired
conversion process (Figure 6E).
Finally, to discriminate between the direct versus indirect
KMT2B targets underlying the impaired transcriptomic remodel-
ing of Kmt2b/ MEF-to-iN transition, we set out to profile its
genome-wide occupancy. To circumvent the lack of ChIP-grade
commercial antibodies against KMT2B, we immunoprecipitated
MENIN, the common subunit exclusive to KMT2A and KMT2B
complexes, in bothKmt2a+/+Kmt2b+/+ andKmt2b/ transdiffer-
entiatingMEFs on day 5.We could thus ascribeMENIN targets in
control samples to both methylases, whereas we defined by
subtraction, as KMT2B-specific targets, the genes that lost
MENIN binding in Kmt2b/ with respect to control cells.
Although the low enrichment of the immunoprecipitation (IP)
could only afford limited sensitivity, we could nevertheless iden-
tify candidate regions with reduced MENIN enrichment, which
we intersected with promoters of genes downregulated and
losing H3K4me3 in Kmt2b/ iNs with respect to controls. This
revealed a core of 12 candidate direct KMT2B target genes dur-
ing iN transition (Figure S5). Importantly, these candidate direct
targets included, again, Arnt2, a central gene of the maturation
subnetwork (Treutlein et al., 2016) that, together with Gnao1,
Chst10, Rtn1, and Gpr135, is related to neuronal specification,
function, and metabolism.
Kmt2b Vulnerability Uncovers Candidate Genes
Associated with Dystonia
It was recently shown that KMT2B mutations can cause early-
onset dystonia (Meyer et al., 2017; Zech et al., 2016), a neurolog-
ical disorder whose additional genetic causes remain still largely
unknown. Indeed, the DEGs in our Kmt2b/ samples were en-
riched for genes whose disruption in the mouse is associated
with dystonia (Atp1a3, Tubb4a, Hpca, and GnaI) or myoclonus
(Npas4, Scn8a, Nhlrc1, Cit, Kcnj11, Slc7a10, Bsn, Mfsd8,Kcna1, and Plaur) (5.7-fold, p  0.0027). Thus, we exploited
the 216 candidate direct KMT2B targets predicted by the inter-
section of DEGs (at FDR < 0.05) and genes that show
H3K4me3 reduction in Kmt2b/ over controls. In particular,
we combined these targets with an analysis of genetic variations
detected through high-throughput sequencing of whole exome-
captured DNA from 225 dystonia patients to define candidate
dystonia-relevant gene variants.
First, the analysis of the exome aggregation consortium
(ExAC) population data revealed that 45 of 216 targets (21%) ex-
hibited probability of being loss-of-function-intolerant (pLI)
scores of 0.9 or higher, 54 (25%) missense Z scores of 2.0 or
higher, and 26 (12%) both pLI scores of 0.9 or higher and
missense Z scores of 2.0 or higher (Lek et al., 2016; Table S2).
Within all targets, 34% of KMT2B target genes were evolutionary
constrained against at least one class of functional variation in
ExAC (Lek et al., 2016), indicating that the KMT2B-sensitive
gene set is enriched for a genomic sequence in which mutational
changes are scarcely tolerated. For most of the KMT2B targets
(79%), we found no known disease annotation (monogenic dis-
ease) in the OMIM database (Table S2).
Under an autosomal dominant disease model, whole-exome
sequencing (WES) yielded 38 unique, predicted deleterious
missense variant across 32 KMT2B targets, 1 each in 38 inde-
pendent probands. Of these variants, 11 affected genes with a
selective constraint against missense variation (missense
Z scores R 2.0). Six genes contained heterozygous missense
variants in more than 1 proband (ALK, DOCK10, KDR, LRP2,
SLC35F1, and SLC40A1). In addition, a total of 7 unique pre-
dicted loss-of-function variants affecting 7 KMT2B targets
were identified among 7 separate probands. Of these variants,
1 resided in a gene with strong loss-of-function intolerance in
the general population (NOL4, pLI score of 1.0). Four variants
in 3 genes emerged as especially promising candidates for
follow-up evaluation (Table 1). In a female proband with child-
hood-onset segmental isolated dystonia and a family history
suggestive of dominant inheritance (case_224), we detected a
c.457C > T (p.Arg153X) stop-gain variant in the NOL4 gene
whose haploinsufficiency is predicted to be non-tolerable
(pLI score of 1.0) (Lek et al., 2016); two male probands with a
strikingly similar presentation of early adulthood-onset tremu-
lous cervical isolated dystonia were each identified to have a
distinct missense variant of the exact same codon 51 in
SLC35F1 (case_112: c.152G > T [p.Arg51Met]; case_122:
c.152G > C [p.Arg51Thr]), a gene constrained against missense
variants (missense Z scores of 2.01) (Figure S6B); and a female
proband manifesting late adulthood-onset cervical isolated dys-
tonia (case_088) was found to harbor a missense variant at
SLC40A1 codon 157 (c.469G > C [p.Asp157His]) (Figure S6C).
Along with the observation that other missense mutations at
this site have been implicated in hemochromatosis type 4
(MIM606069) (Callebaut et al., 2014; Hetet et al., 2003), a multi-
system iron deposition disorder, this finding led us to reverse-
phenotype this proband and uncover elevated serum ferritin
levels as well as bilateral signal alterations on brain MRI in a
pattern consistent with brain iron deposition (data not shown).
Finally, to complete a comprehensive assessment of the muta-
tional architecture in KMT2B targets among dystonia cases,Cell Reports 25, 988–1001, October 23, 2018 997
Table 1. Candidate variants in 4 probands with dystonia
Disease
model Gene
pLI
score
(ExAC)
missense
Z score
(ExAC)
Known
disease
annotation
(OMIM)
Variation
nucleotidea
Variation
amino
acida
Variant
type
Frequency
ExAC;
dbSNP142
Frequency
in-house
exomesb
CADD
score Carrier # Sex
Age at
onset, y
Dystonia
type
Family
history
Comment
on putative
disease
relevance
Autosomal-
dominant
NOL4 1.0 2.7 no c.457C>T p.Arg153X stop-
gain
not found;
not found
not found 37 case_224 F 4 segmental
isolated
dystonia
(cervical
dystonia,
upper limb
dystonic
tremor)
positive loss-of-
function
variant in
gene with
pLIR0.9
Autosomal-
dominant
SLC35F1 0.39 2.01 no c.152G>T p.Arg51Met missense not found;
not found
not found 30 case_112 M 26 focal
isolated
dystonia
(tremulous
cervical
dystonia)
negative mutational
recurrence
at codon-
51 in gene
with missense
Z scoreR2.0
Autosomal-
dominant
SLC35F1 0.39 2.01 no c.152G>C p.Arg51Thr missense not found;
not found
not found 24 case_122 M 33 focal
isolated
dystonia
(tremulous
cervical
dystonia
negative mutational
recurrence at
codon-51 in
gene with
missense
Z scoreR2.0
Autosomal-
dominant
SLC40A1 0.98 1.77 MIM606069 c.469G>C p.Asp157His missense not found;
not found
not found 31 case_088 F 44 focal
isolated
dystonia
(cervical
dystonia)
positive mutational
recurrence at
codon-157,
a site previously
associated with
hemochro-
matosis 4
Sex:M =male, F = female. ExAC= exome aggregation consortium, Cambridge,MA (http://exac.broadinstitute.org). pLI = probability of being loss-of-function intolerant. OMIM=OnlineMendelian
Inheritance in Man (https://omim.org/). CADD = Combined Annotation Dependent Depletion.
anumbering according to NCBI accessions NM_003787.4 and NP_003778.2 for NOL4, NM_001029858.3 and NP_001025029.2 for SLC35F1, NM_014585.5 and NP_055400.1 for SLC40A1, and
NM_006931.2 and NP_008862.1 for SLC2A3.
bconsisting of roughly 10,000 non-dystonia control exomes.
9
9
8
C
e
llR
e
p
o
rts
2
5
,
9
8
8
–
1
0
0
1
,
O
c
to
b
e
r
2
3
,
2
0
1
8
we analyzed two additional murine datasets of KMT2B-vulner-
able genes from brain neurons (Kerimoglu et al., 2013) and
ESCs (Denissov et al., 2014), respectively (Table S3), scoring
them against the same panel of 225 exomes from dystonia pa-
tients. We found that the deletion of Kmt2b in these different
cellular systems led to the identification of different targets
and that the percentage of candidate dystonia-causative
genes was different in the three cellular types. Specifically, the
percentage of dystonia candidate genes was significantly higher
in the iN versus ESC set of KMT2B targets for pLi score (Table
S4), suggesting that transdifferentiation uncovers greater vulner-
ability in the KMT2B-dependent pathways at play in dystonia.
DISCUSSION
Here, we showed that KMT2B is required for the BAM-mediated
epigenome remodeling that underlies the MEF-to-iN conversion
and that the molecular unravelling of this phenotype exposes
dystonia candidate genes. In particular, we demonstrated, for
KMT2B, a dual role in the promotion of iN conversion through
suppression of the alternative myocytic fate as well as in iN
maturation. In contrast, KMT2A proved dispensable and, despite
being a paralog of KMT2B, was unable to replace it in transdiffer-
entiation. Beyond identification of the first chromatin regulator
essential for MEF-to-iN conversion, our findings support the
following conclusions about the specificity of direct neuronal
programming.
First, the requirement for KMT2B in iN generation only partially
recapitulates its function during both in vitro and in vivo neuronal
differentiation. In vitro, Kmt2b/ ESCs present an impaired dif-
ferentiation to neurons (Lubitz et al., 2007), whereas the deletion
of Kmt2b in excitatory forebrain terminally differentiated neurons
did not impinge brain morphology macroscopically but impaired
memory formation and affected H3K4me3 deposition (Kerimo-
glu et al., 2013, 2017). This notwithstanding, we found high
convergence in vulnerable H3K4me3 sites upon loss of KMT2B
between in vivo matured neurons and transdifferentiated iNs.
Conversely, the dispensability of KMT2A inMEF transdifferentia-
tion stands in stark contrast with its essential role during
neuronal differentiation, as observed both in murine SVZ (Lim
et al., 2009) and in D. rerio (Huang et al., 2015). Together, these
results highlight how different origins and/or transition paths to
similar developmental endpoints (namely, transdifferentiation
and differentiation) expose distinct epigenetic requirements.
This, in turn, has major implications for the choice of program-
ming or reprogramming paradigms in disease modeling and
regeneration, especially when they are intended to model or
remedy deficits in epigenetic regulation.
Second, we previously showed that the defective response to
lipopolysaccharide (LPS) in Kmt2b/macrophages was imput-
able to a single downstream gene, Pigp, which aberrantly
accumulated H3K27me3 (Austenaa et al., 2012). In MEF-to-iN
transition, instead, we found that loss of KMT2B leads to
massive transcriptional dysregulation and H3K4me3 redistribu-
tion that affects, starting already at the MEF level, the whole
program of iN fate acquisition and maturation rather than
specific master regulators, pointing to distinct logics of cell
fate control downstream of the same chromatin modifier.Third, the presence of H3K4me3 at lineage-specific genes has
been recently proposed as a molecular roadblock to reprogram-
ming in the nuclear transfer (NT) paradigm (Ho¨rmanseder et al.,
2017), leading to a model in which H3K4me3-dependent
memory of transcriptional status in donor cells limits the reprog-
ramming of their developmental potential. H3K4me3 inhibition in
somatic cells thus favors their reacquisition of pluripotency but
disables their ability to undergo inter-lineage cell conversion.
Because the H3K4me3 inhibition upon NT was carried out by
overexpressing the H3K4 demethylase Kdm5b, likely its global
effects are neither directly comparable with nor symmetrical to
our setting, in which the bulk H3K4me3 axis (operated by
KMT2E and KMT2F) was left intact. It is worth noting, however,
that inhibition of H3K4 demethylase LSD1 (KDM1A) promotes
TF-induced reprogramming to pluripotency (Cacchiarelli et al.,
2015). Thus, this symmetrical convergence with our findings
points to a fundamental distinction in how NT- versus TF-based
reprogramming handles H3K4me3 dynamics.
Finally, our work innovatively exploited transdifferentiation as a
tool for the identification and prioritization of candidate causative
variants. Because KMT2B loss-of-functionmutations lead to dys-
tonia (Meyer et al., 2017; Zech et al., 2016), we reasoned that the
KMT2B-vulnerable targets exposed through theMEF-to-iN transi-
tion could guide our search for dystonia-relevant variants and
genes in whole-exome sequences of dystonia patients. Indeed,
we found, in 39 KMT2B targets, 45 unique protein-impactful alter-
ations, including mutations in 3 promising candidates: NOL4,
SLC35F1, and SLC40A1. NOL3, notable for its relationship to
NOL4, has been previously associated with myoclonus (Russell
et al., 2012), whereas for SLC35F1, we found a mutational recur-
rence at the same codon in 2 probands with very similar pheno-
types. Finally, for SLC40A1, we scored a mutational recurrence
at a codon previously associated with hemochromatosis type 4
and, therefore, with iron deposition. The proband was found to
have elevated serum ferritin and possibly iron deposits on brain
MRI (bilateral signal alterations of basal ganglia), in line with signal
alterationsofbasal gangliadescribed inmostKMT2B-mutatedpa-
tients (Meyer etal., 2017) thathadnot yetbeenassociatedwith iron
deposits, raising the intriguingpossibility that the brain signal alter-
ations seen inKMT2Bprobandsmight bedue to ironabnormalities
induced by SLC40A1-mediated downstream effects. Together,
these data offer a compendium of promising candidates that are
now opened up for further validation, following the recent trend
in humangenomics inwhichmutations originally uncovered in sin-
gle individuals are eventually consolidated in the definition of syn-
dromes (Vissers et al., 2010; Gabriele et al., 2017).EXPERIMENTAL PROCEDURES
MEF Derivation
MEFs were derived from mice with cKO for Kmt2a (Kranz et al., 2010), Kmt2b
(Glaser et al., 2006), or both methylases and housed and bred in a specific
pathogen-free animal house. Control MEFs were derived from Kmt2+/+YFP+
Cre+ embryos and, in the case of Kmt2a, also from Kmt2afl/+YFP+Cre+ ones.
See the Supplemental Experimental Procedures for further details.
Mouse Experiments
Experiments involving animals were carried out in accordance with the Italian
Law (D.lgs. 26/2014) that enforces Directive 2010/63/EU of the EuropeanCell Reports 25, 988–1001, October 23, 2018 999
Parliament and of the Council of 22 September 2010, on the protection of ani-
mals used for scientific purposes. The project started before the passing of
D.lgs. 26/2014 and was thus notified to the Ministry of Health before the imple-
mentation of the current legislation. As the new legislation does not apply to pro-
jects approved before its enactment, for such projects only a notification of the
experiments to the Ministry of Health was required (in accordance with the
D.L.vo 116/92 [and following additions], which enforced EU 86/609 Directive),
and this requirementwas dutifully fulfilled. Following the coming into force of Ital-
ian Law (D.lgs. 26/2014) and the expiration of the previously notified project, we
submitted for the continuation of the project a new application to the Ministry of
Health that granted us the authorization under Project n 385/2016.
Immunofluorescence
MEFs were seeded with different cell densities in Nunc Lab-Tek Permanox
chamber slides (Sigma-Aldrich) in duplicates. 3 and 13 days after plating for
transduction, cells were stained and acquired with a BX61 upright microscope
equipped with a motorized stage from Olympus. The software ScanR
(Olympus) was used, and the objective utilized was 203 with a 0.75 numerical
aperture. See the Supplemental Experimental Procedures for further details.
Cytofluorimetric Analysis
The PSA-NCAM antibody used is listed in Table S7. 3 min before each tube
was acquired, 5–10 mL of propidium iodide (PI) (Sigma-Aldrich, P4170-1G)
was added. Samples were acquired at BD FacsCalibur with the BD CellQuest
Pro software and analyzed with the Flowjo software. Unpaired t test was
executed. See the Supplemental Experimental Procedures for further details.
FACS
FACS was executed on 4-OHT-treated MEFs left in culture 7 days before
transdifferentiation. MEFs were plated on Matrigel-coated dishes both for
RNA-seq and the ChIP-seq on iNs at 13 days. Cells were sorted for PSA-
NCAM positivity at MoFlo Astrios (Beckman Coulter) with the software Summit
v6.2. The negative PSA-NCAM fraction was kept as well.
RNA-Seq
RNAwas extractedwith the RNeasymicro kit (QIAGEN). RNA quality was eval-
uated with the Agilent 2100 Bioanalyzer. Total RNA was depleted of rRNA with
Ribo-Zero, and libraries were prepared with the TruSeq Stranded Total RNA
Sample Preparation Kit (Illumina) starting from 100 ng of RNA per sample
and sequenced with the Illumina HiSeq machine at a read length of 100 bp,
paired ends, and a coverage of 120 million reads. See the Supplemental
Experimental Procedures for further details.
ChIP-Seq
ChIP-seq for MENIN was performed on bulk 5-day transdifferentiating MEFs,
ChIP-seq for H3K4me3 onMEFs 2 and 7 days after the last 4-OHT administra-
tion, on the whole-cell population at 5 days, and on PSA-NCAM+ cells at
13 days. H3K27me3 ChIP-seq was performed on MEFs 2 and 7 days after
the last 4-OHT administration and on the whole-cell population at 5 days.
See the Supplemental Experimental Procedures for further details.
Exome Analysis
WES and analysis of all 225 dystonia subjects was performed as described
previously (Zech et al., 2016, 2017). Assuming that causative mutations in
the proband cohort are coding alleles of strong effect, we searched the full
WES dataset for missense, in-frame insertion or deletion (indel), stop-gain
and stop-loss, frameshift, and splice site variations in any of the KMT2B-
sensitive genes (Figure S6A). Filtered variants were considered under both
an autosomal dominant (1 heterozygous variant per gene per proband) and
an autosomal recessive disease model (homozygous variant or 2 heterozy-
gous variants per gene per proband). See the Supplemental Experimental
Procedures for further details.
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Figure S1. The role of KMT2A and KMT2B during transdifferentiation, related to Figure 2
A, Percentage of YFP+ cells among PSA-NCAM+ cells 5, 7, 9 and 13 days after plating in
Kmt2a+/+Kmt2b+/+ (n=2) and Kmt2a+/+Kmt2bfl/fl (n=2) 4-OHT transdifferentiating MEFs. B, The
graph shows Kmt2b exon usage in Kmt2bfl/fl (in blue) and Kmt2b+/+ (in red) 4-OHT treated 13-
days sorted iNs obtained through RNA-seq analysis. C, Efficiency of transdifferentiation in
ScanR experiments calculated relating the number of Tuj1+ at 13 days, of the chosen
concentration, to the number of DAPI 3 days after plating. D, Cell mortality in ScanR
experiments calculated as the ratio of DAPI 3 days (DAPI start) and 13 days (DAPI end) after
plating. In C-D, 2 independent experiments (exp1 and exp2) were performed and cells were
plated 2 days after the last 4-OHT administration. E, Percentage of dead cells was calculated
over the initial number of plated MEFs 2, 5 and 9 days after the first 4-OHT administration. F,
Mortality rate as percentage of PI+ cells 2, 5 and 9 days after the first 4-OHT administration. E-
F Kmt2a+/+ Kmt2b+/+ n=5; Kmt2afl/fl Kmt2bfl/fl n=3. G, I, K, Percentage of dead cells was
calculated over the initial number of plated MEFs. (G) Kmt2afl/fl n=3; Kmt2a+/+ n=3 at all time
points, but day 21: n=2. (I) Kmt2a+/+ Kmt2b+/+ n=1; Kmt2a+/+ Kmt2bfl/fl n=2 despite day 9 n=1.
(K) Kmt2a+/+ Kmt2b+/+ n=3; Kmt2afl/fl Kmt2bfl/fl n=3. H, J, L, Mortality rate as percentage of PI+
cells 5, 7, 9, 13 (and 21 for (H)) days after plating, assayed with FACS analysis. (H) Kmt2afl/fl
n=3 at all time points, but day 21 in which n=2; Kmt2a+/+ n=3 at all time points, but day 21 in
which n=1. (J) Kmt2a+/+ Kmt2b+/+ n=1; Kmt2a+/+ Kmt2bfl/fl n=2. (L) Kmt2a+/+ Kmt2b+/+ n=3;
Kmt2afl/fl Kmt2bfl/fl n=3. A-L, Error bars show means +/- SEM. A-B, G-L, MEFs were plated for
transdifferentiation 7 days after the end of 4-OHT treatment.
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Figure S2. KMT2B is fundamental for iN maturation while KMT2A is dispensable,
related to Figure 2
Representative images of Kmt2bfl/fl and Kmt2b+/+ 4-OHT transdifferentiated MEFs at 13
days, plated either 2 (A) or 7 (B) days after 4-OHT, of Kmt2afl/fl and Kmt2afl/+ (used as
control instead of Kmt2a+/+) 4-OHT transdifferentiated MEFs at 13 days, plated 2 days
after 4-OHT (C) and of Kmt2a+/+Kmt2b+/+ and Kmt2afl/fl Kmt2bfl/fl 4-OHT
transdifferentiated MEFs at 13 days, plated 2 days after 4-OHT (E). The grid of images
built for KO and ctrl was the same. Images taken in the same areas of the well are
reported for cKOs and control. DAPI is in blue and Tuj1 in red. D, Representative images
of Kmt2afl/+ (used as alternative control to Kmt2a+/+) (left panel) and fl/fl (right panel) 4-
OHT treated iNs (DAPI is in blue, Tuj1 in red, MAP2b in green) at 13 days.
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Figure S3. Transcriptomic analysis of PSA-NCAM+ cells, related to Figure 3
A, PCA on the log-normalized read counts of Kmt2a+/+ Kmt2b+/+ (CTRL_A1, CTRL_A3,
CTRL_A6, CTRL_I15, CTRL_I17) and Kmt2b-/- (KO_F16, KO_F11, KO_F17, KO_E10, KO_E11)
transcriptomes of sorted PSA-NCAM+ cells at 13 days. B, PCA on the log-normalized read
counts of Kmt2a+/+ Kmt2b+/+ (CTRL_A6, CTRL_I15, CTRL_I17) and Kmt2b-/- (KO_F16, KO_F11,
KO_E10) transcriptomes of sorted PSA-NCAM- cells at 13 days. C, Validation through RT-qPCR
of some of the genes differentially expressed with an impact on the in vitro phenotype. Error
bars show means and SD. *** p<0.0001; ** p<0.001; *p<0.01. Spearman (D) and Pearson (E)
correlation of the Kmt2b cKO and control iNs transcriptomes vis à vis the different previously
reported fates of single cells undergoing transdifferentiation (Treutlein et al., 2016). A1, A3, A6,
I15, I17 and E11, E17, E10, F11, F16 are the names of the embryos from where
Kmt2a+/+Kmt2b+/+ and Kmt2a+/+Kmt2bfl/fl MEFs were derived, respectively.
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Figure S4. Epigenomic and transcriptomic dissection, related to Figure 6
A, Union of loci showing significant changes in H3K4me3 in Kmt2b cKO at day 5 and/or 13. B,
Heatmap of the genes that further lose H3K4 trimethylation in Kmt2b cKO samples at 13 days
and their expression in RNA-seq at 13 days. C, FPKM of Runx1t1 in our RNA-seq * FDR<0.01.
Error bars show means and SD. A1, A3, A6, I15, I17, L1, L6, L7 and E11, E17, E10, F11, F16,
M6, M7 are the names of the embryos from where Kmt2a+/+Kmt2b+/+ and Kmt2a+/+Kmt2bfl/fl
MEFs were derived, respectively. B1 is the name of the embryo from where Kmt2afl/flKmt2b+/+
MEFs were derived.
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Figure S5. Identification of KMT2B candidate targets through MENIN ChIPseq, related to
Figure 6
Heatmap showing the genes both differentially bound by MENIN, differentially expressed (FDR
<0.01 and a FC > 0.5) and differentially H3K4me3 in Kmt2b-/- with respect to control. A1, A3, A6,
I15, I17, L6, L7, L1 and E11, E17, E10, F11, F16, M6, M7 are the names of the embryos from
where Kmt2a+/+Kmt2b+/+ and Kmt2a+/+Kmt2bfl/fl MEFs were derived, respectively. B1 is the name
of the embryo from which Kmt2afl/fl MEFs were derived.
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Figure S6. Identification of new putative dystonia-causing variants and genes,
related to Table 1
A, Experimental pipeline of variant calling and filtering. B-C, Schematics of SLC35F1 and
SLC40A1 mutations generated with Protter: interactive protein feature visualization and
integration with experimental proteomic data (Omasits et al., 2014).
Table S1. Summary of all experiments performed at ScanR, related to Figure 2 
Table S4. Summary of the Tables S1 and S2, related to Table 1. χ2 test: p < 0,005 iN vs
ESC, pLI: 0,00024; iN vs ESC, misZ: 0,58; iN vs ESC, both 0.7.
Number of KMT2B targets pLI  ≥ 0.9 Missense Z score  ≥ 2 Both
iNs 216 45 (21%) 54 (25%) 26 (12%)
Brain Neurons 127 5 (4%) 11 (9%) 6 (5%)
ESCs 120 9 (7%) 26 (21%) 12 (10%)
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No. (sex female/male) 225 (133/92) 
Age at samplinga 50.4 ± 14.6 (18-88) 
Age at onseta 29.4 ± 15.1 (1-69) 
Early symptom onset (<30 years) (%) 48.0 
Family history positive (%) 38.7 
Dystonia distribution (%)  
 Focal 61.8 
 Segmental 20.0 
 Generalized 18.2 
Dystonia clinical classificationb (%)  
 Isolated 87.9 
 Combined 5.6 
 Complex 6.5 
Table S5. Clinical characteristics of 225 dystonia-affected probands sequenced by
exome, related to Table 1
aMean age in years ± standard deviation (range); baccording to Albanese et al., 2013
and Marras et al., 2016
 
aMean ± standard deviation (range) 
N= Readsa Mapped readsa Percenta Mapped sequence (Gb)a 
Target bases > 
20xa 
Average 
coveragea 
225 129,920,660 ± 18,380,126 (80,589,549-185,236,854) 
129,366,209 ± 18,479,892  
(79,579,741-184,924,819) 
99.55 ± 0.36 
(98.74-99.95) 
13.14 ± 2.16 
(8.04-27.92) 
98.49 ± 0.49 
(96.47-99.31) 
153.54 ± 22.04 
(98.46-264.60) 
Table S6. Summary of statistics for 225 dystonia exomes, related to Table 1 
Table S7. List of antibodies used in the study, related to Experimental Procedures
Table S8. Sequences of primers used in RT-qPCR, related to Experimental Procedures
	
 Forward Reverse 
ApoE CAATTGCGAAGATGAAGGCTC TAATCCCAGAAGCGGTTCAG 
Magohb CGGGCATAAGGGCAAGTTT AATTACTGTTGTTGGCATATGTAAGCTT 
Myo16 TGTGTCCAGTTGCCTCATAC CAGGAGAAAATCAGAAAGGTGC 
Nefl GGGTATGAACGAAGCTCTGG TCTCAGCTCATTCTCCAGTTTG 
Plp1 TCAGCCGCAAAACAGACTAG CACTCCAAAGAAACACAATCCAG 
Rtn1 GTGTGGAGCAACTGGAAAAG CTCCCGAACACAATCCCAG  
Syngr1 GGACAACCCTCTGAACGAAG CCAATCTGGTACCTCTGGAAG 
Syp TGCAGTGGGTCTTTGCCATCTT ACTTCGATGTTGAGGGCACTCT 
Syt16 TCCATACGTCAAAGTCTTCCTG TGTCTTGCCACCTAATTCCG 
Zfp238 TCTCCACTTTGCATCTGTCTC TGCTGTGGTCTGGAAACTC 
	
KMT2B rabbit Stewart Lab  1:1000 WB 
VINCULIN mouse Sigma Aldrich V9131 1:400 WB 
TUJ1 mouse Covance MMS-435P 1:400 IF 
TUJ1 rabbit Covance MRB-435P 1:400 IF 
VIMENTIN mouse Abcam ab20346 1:200 IF 
MAP2B mouse BD Biosciences 610460 1:500 IF 
H3K4me3 rabbit Active motif 39159 1ug Ab each 
100 ug 
Cromatin 
ChIP 
H3K27me3 rabbit Cell signaling 9733BF 1ug Ab each 
25 ug 
Cromatin 
ChIP 
MENIN rabbit Abcam ab31902 1ug Ab each 
100 ug 
Cromatin 
ChIP 
PSA-NCAM mouse Miltenyi 130-093-
273 
 FACS 
	
Supplemental Experimental Procedures 
 
MEFs derivation 
MEFs were derived from embryos at E13.5. After removal of both the head and the 
liver, cells were enzymatically and mechanically dissociated through the incubation 
with trypsin at 37° C, 3% O2, 5% CO2 for 30 minutes, pipetting every 10 minutes. 
Dissociated MEFs were seeded in the medium published in the original paper 
(Vierbuchen et al., 2010) and cultured at 37 °C, 3% O2 and 5% CO2. 
Control and cKO MEFs at P1-P3 were treated for 5 days with 4-Hydroxytamoxifen (4-
OHT), added to the MEF medium in a final concentration of 1000 ng/ml, and then left 
either 2 or 7 days in medium not supplemented with 4-OHT.  
Transdifferentiation was performed according to the protocol published in the original 
paper (Vierbuchen et al., 2010). 
Mice/MEFs were genotyped using the following primers: YFP: forward-5’-
TGCAGTGCTTCGCCCGCTACC-3’ and reverse-5’-CCGTCGCCGATGGGGGTGTT 
C-3’ (Mihailovich et al., 2015); Cre: forward-5’-GCCTGCATTACCGGTCG 
ATGCAACGA-3’ and reverse-5’-GTGGCAGATGGCGCGGCAAACCATT-3’ (Basch 
et al., 2011); Kmt2a forward-5’-GAGGTAAGGAGAGTTTTTGCT-3’ and reverse-5’-
GGTAACACCTTAAAATGCCCT-3’ (Kranz et al., 2010); Kmt2b: forward-5’-
CGGAGGAAGAGAGCAGTGACG-3’ and reverse-5’-GGACAGGAGTCACATCTGCT 
AGG-3’ (Glaser et al., 2006). 
 
Assessment of exon 2 deletion of both Kmt2a and Kmt2b 
To determine the entity of Kmt2 exon 2 deletion, TaqMan assays were performed 
extracting DNA, through DNeasy Blood and Tissue kit (Qiagen), the day MEFs were 
plated for transdifferentiation. In particular, Real Time PCR was performed on 
7900HT Fast Real-Time PCR system (Applied Biosystems). Primers were the 
following: 
MLL2EX2: forward-5’-GGTCCCCTAAATCAGGAGTTTCAG-3’, reverse-5’-GACCG 
AAGCGCAGAGC-3’, reporter sequence-5’-AAGATGTGGCCCCCAGTTC-3’. 
MLL1EX2: forward-5’-GCAGTTCTTAGGTTTTGGCTCAGA-3’, reverse-5’-GCTTTAT 
TGGCCATACCTGAAGGA-3’, reporter sequence-5’-CTTCGCACTCTGACTTCTTCA 
-3’. 
Western blot for KMT2B 
Proteins were extracted in RIPA buffer (10 mM Tris-HCl pH 8, 1% Triton X-100, 0.1% 
SDS, 0.1% Sodium Deoxycholate, 140 mM NaCl, 1 mM EDTA plus the protease 
inhibitor cocktail (PIC) (Sigma Aldrich) and Phenylmethanesulfonyl fluoride (PMSF) 
(0.5 mM) (Sigma Aldrich) from at least 8 x 106 MEFs, the day were plated for 
transdifferentiation. 
At least 70 μg of protein extract was loaded into the NuPAGE Novex 3-8% Tris-
Acetate Proteins Gels (ThermoFisher Scientific) and run in the NuPAGE Tris-Acetate 
SDS Running buffer (20X) (ThermoFisher Scientific). Wet transfer was performed at 
4 °C, 30V with the Immobilon-P, 0.45 μm, PVDF membrane (Merck Millipore) 
overnight. Antibodies used are listed in Table S7. 
 
Vector production 
BAM and rtTA vectors were generated through calcium phosphate transfection of 
human embryonic kidney 293T (HEK293T) cells and ultracentrifugation. The 
following transfer plasmids, deposited by the Wernig Lab in Addgene, were used 
(Tet-O-FUW-Brn2, Tet-O-FUW-Ascl1, Tet-O-FUW-Myt1l and UbC-rtTA). BAM 
vectors were produced using a third generation system (envelope plasmid: pMD2-
VSV-G; packaging plasmids: pMDLg/pRRE and pRSV-REV).  
 
Image acquisition and analysis: efficiency and cell mortality calculation 
Cells were fixed with 4% paraformaldehyde (PFA), 20 minutes on ice and 
permeabilized with PBS, 10% FBS, 0.1% Triton X-100, 30 minutes at room 
temperature (RT). Cells were incubated with primary antibodies (listed in Table S7), 
overnight at 4°C, and then with secondary antibodies 1 h at RT. Primary and 
secondary antibodies were diluted in PBS, 10% FBS. DAPI (SIGMA D9542) was 
added to the secondary antibodies mix. A grid of 100 images per embryo in duplicate 
was acquired. Through ScanR we covered an area of ~ 14 mm2 per cell density, in a 
grid of 100 images equidistant from each other, maintaining the same setting across 
conditions and time points and we acquired at least 1000 cells at day 3 and 500 cells 
at the following time point. 3 days after plating the number of cells per image was 
manually evaluated as number of DAPI in each cell density condition. At 13 days 
only conditions that at day 3 were in the same number were compared. Cells positive 
for Tuj1 were classified as iNs and manually quantified.  
The number of DAPI at day 3 and day 13, of the chosen cell density, were summed 
and called DAPI start and DAPI end, respectively. To calculate cell mortality the ratio 
between DAPI start and DAPI end was calculated, assuming that the cells distribute 
almost equally in the two duplicate wells (i.e., day 3 and day 13) of each condition. 
Then, to calculate efficiency, the number of Tuj1+ cells at day 13 was related to the 
number of DAPI start: 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑇𝑢𝑗1-./012𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝐷𝐴𝑃𝐼-./1 % 
NeuriteTracer was used to calculate neurite length (Pool et al., 2008). Because this 
calculation depends on the number of neurons the plugin-retrieved value was divided 
for the number of Tuj1+ cells. Unpaired t test was performed as statistical analysis. 
 
Cytofluorimetric analysis: efficiency and cell mortality calculation 
Before cytofluorimentric analysis cells were counted through the Automated Cell 
Countess (Thermo Fisher Scientific) 5, 7, 9, 13 and 21 days after they were plated 
for transdifferentiation. Cell mortality was reported as the percentage of dead cells 
with respect to the number of plated cells: 𝑁	𝑜𝑓	𝑝𝑙𝑎𝑡𝑒𝑑	𝑐𝑒𝑙𝑙𝑠 − 𝑁	𝑜𝑓	𝑎𝑙𝑖𝑣𝑒	𝑐𝑒𝑙𝑙𝑠-./01𝑁	𝑜𝑓	𝑝𝑙𝑎𝑡𝑒𝑑	𝑐𝑒𝑙𝑙𝑠 % 
Knowing the percentage of PSA-NCAM+ cells and the absolute number of cells at 
day 13, the absolute number of PSA-NCAM+ iNs was calculated. This value was 
related to the number of plated cells to calculate the efficiency of transdifferentiation: 𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑃𝑆𝐴 − 𝑁𝐶𝐴𝑀-./012𝑛𝑢𝑚𝑏𝑒𝑟	𝑜𝑓	𝑝𝑙𝑎𝑡𝑒𝑑	𝑐𝑒𝑙𝑙𝑠-./F % 
FACS sorting 
FACS sorting was executed on 4-OHT treated MEFs left in culture 7 days before 
transdifferentiation. 107 MEFs were plated on matrigel coated dishes both for the 
RNA-seq and the ChIP-seq on iNs at 13 days. Cells were sorted for PSA-NCAM 
positivity at MoFlo Astrios (Beckman Coulter) with the Software Summit v6.2. 
 
RNA-seq analysis 
RNA-seq reads were aligned with TopHat v2.0.10 (Trapnell et al., 2012), first to 
mm10 Refseq transcriptome, and genes without a perfect alignment were realigned 
to genome (--read-realign-edit-dist=1), tolerating an edit distance of 3. Quantification 
was performed on the Refseq transcriptome using Cuffquant v2.2.1, with multi-read 
correction (-u) (Trapnell et al., 2012). This pipeline was selected because it was one 
of the highest-performing quantification methods in our recent benchmark (Germain 
et al., 2016).  
For the differential expression analysis, we first excluded genes which had an 
average read count across samples below 50. We used edgeR v.3.12.1 (which 
outperformed other methods according to our benchmark) with TMM normalization 
and the exact test on the estimated fragment counts. We considered differentially 
expressed with high confidence genes with a FDR below 0.01 and an absolute 
log2(foldchange) greater than log2(1.5). Differential exon usage analysis was 
performed with DEXSeq. 
 
Gene Ontology enrichment analyses 
Gene Ontology enrichment analyses were performed using the goseq v.1.22.0 R 
package for RNAseq results in order to correct for RNA-seq transcript length bias 
(Young et al., 2010), or with the topGO package for ChIPseq results, in both cases 
using Fisher’s test and excluding genes without annotation. Categories with at least 
10 genes and maximum 1500 genes were considered. When the number of enriched 
categories was large, we focused on the most specific categories by removing any 
category with enriched children categories. Quilts were generated using treemap R 
package.  
 
RNA-seq validation 
The RNA was retrotranscribed through the SuperScript VILO cDNA Synthesis Kit 
(Invitrogen, 11754-050). 
Real Time Quantitative PCR (RT-qPCR) was performed on 7500 Fast Real-Time 
PCR system (Applied Biosystems) using Sybr green (Applied Biosystems) as 
detecting reagent and the standard amplification protocol. Primers used are reported 
in Table S8. Primers for Magohb are described in the paper of Ladopoulus et al 
(Ladopoulos et al., 2013), while the ones for Syp in (Simon et al., 2016). 
ChIP-seq 
At the desired time point, cells were fixed with PBS 1% formaldehyde. Fixation was 
quenched with 0,125M glycine. Cells were collected in SDS Buffer (100mM NaCl, 
50mM Tris-HCl pH 8.1, 5mM EDTA pH 8, 0.5% SDS), centrifuged, then resuspended 
in 3 ml of ice-cold IP buffer (2 volumes SDS Buffer: 1 volume Triton Dilution Buffer) 
(Triton Dilution Buffer: 100mM NaCl, 100mM Tris-HCl pH 8.6, 5mM EDTA pH 8, 5% 
Triton X-100) and sonicated through the Digital Sonifier 450 (Branson) (ChIP-seq for 
Menin: 700-bp DNA fragments; ChIP-seq for H3K4me3 and H3K27me3: 200-bp DNA 
fragments). Immunoprecipitation was performed in IP buffer using the antibodies 
listed in Table S7. 
The immunoprecipitated product was purified through Protein G dynabeads 
(ThermoFisher Scientific, 10003D), afterwards washed with low-salt (150mM NaCl, 
20mM Tris-HCl pH 8, 2mM EDTA pH 8, SDS 0.1%, 1% Triton X-100) and high-salt 
wash (500mM NaCl, 20mM Tris-HCl pH 8, 2mM EDTA pH 8, SDS 0.1%, 1% Triton 
X-100) buffer 3 times with 1 ml of 150 mM Wash Buffer and once with 1 ml of 500 
mM Wash Buffer with the use of a Dynamag magnet (ThermoFisher Scientific, 
catalog number 12321D). 
Decrossilinking occurred through the incubation of beads (and the 1% input) with 
Decrosslinking Buffer (1% SDS, 0.1M NaHCO3) at 65 °C overnight. DNA was purified 
with the QiaQuick PCR Purification kit (Qiagen) following manufacturer’s instructions. 
Libraries were prepared as previously described (Adamo et al., 2015) and 
sequenced on a HiSeq 2000 instrument (Illumina) following manufacturer's protocol. 
Sequencing was performed in single end, 50 bp, with a coverage of 30 millions of 
reads for inputs, H3K4me1 and menin ChIP-seq and 60 millions for H3K27me3. 
ChIP-seq reads were trimmed for potential adapter contamination using scythe 0.981 
(min 4 nucleotides) before being aligned to the mm10 genome using bowtie 1.0 
(Langmead et al., 2009) with –v 2 –m 1, and peaks were called using MACS 2.0.9 
(Langmead et al., 2009; Zhang et al., 2008) with default settings. Although we relied 
mostly on quantitative analyses (below) to compare across replicates and conditions, 
when comparing peaks directly we considered peaks as overlapping if they shared at 
least one nucleotide.  
Proximally bound genes were defined as having a peak within a -2.5kb/+1kb window 
around any of their RefSeq TSS. To identify the putative targets of intergenic sites 
bound by MENIN but in contact with a TSS only through chromatin conformation, we 
relied on Hi-C data from the most similar cell type available, namely neural 
progenitors. We downloaded already processed, statistically significant interactions 
from the Gene Expression Omnibus entry GSE68582, extracted a bed file containing 
each region interacting with a RefSeq TSS, and intersected it (using intersectBed) 
with our regions of interest to find distal targets. 
Peak calling is very sensitive to coverage and technical variation, and quantitative 
analysis of read distribution yields considerably more robust findings. To find 
differences across conditions, we therefore worked on the distribution of reads falling 
within relevant genomic windows. For each protein/mark, the windows were defined 
by merging the enriched regions across samples (i.e., with BedTools: cat *.bed | 
sortBed -i - | mergeBed -i -). In this way, all regions enriched in at least one sample 
were considered for statistical testing, without duplicate genomic regions. The read 
counts were then compared across conditions with edgeR v.3.12.1 (Robinson et al., 
2010),  using the total number of mapped reads as library size and the TMM method 
for normalization. Differentially enriched regions were identified using the classical 
dispersion model of edgeR (based on a negative binomial model) and the exact test.  
For the MENIN ChIP-seq, given the low quality of the peak calling (very low and 
variable number of peaks across samples, probably owing to a low and highly 
variable coverage), we performed a peak-call-agnostic differential enrichment 
analysis using diffReps (Shen et al., 2013), which uses sliding windows to directly 
identify regions of significant difference between sets of enrichment profiles.  
 
Data representation (RNA-seq and ChIP-seq) 
Principal component analyses were performed on the normalized, log-transformed 
read counts (+1 was added before log-transform to avoid errors on null values). 
Unless specified otherwise, all heatmaps show row z-scores of log-transformed 
normalized counts. Heatmaps were produced using the pheatmap R package. 
 
External data (RNA-seq and ChIP-seq) 
For external datasets, we used the authors' original peak calls (ChIP-seq) or 
quantification (RNA-seq) that are available from the respective GEO entries.  
 
Exome analysis 
The list of Kmt2b dependent genes was predicted by the intersection between DEGs 
(at FDR < 0.05) and genes with H3K4me3 reduction in Kmt2b cKO 
transdifferentiating MEFs with respect to controls. To test the hypothesis that the 
coding regions of KMT2B-sensitive genes are an untapped reservoir of dystonia-
causing mutations, we queried a large repository of whole-exome sequencing (WES) 
data from a European-descent dystonia cohort. Accrued from movement disorders 
centers in Munich (Germany), Innsbruck (Austria), and Prague (Czech Republic), this 
cohort comprised 225 unrelated probands with various types of dystonic 
presentations in whom disease had not been explained. The recruitment strategy 
and clinical characterization process have been described previously (Zech et al., 
2017) and demographics as well as phenotypic information of the cohort can be 
found in Table S5. The cohort was enriched for possible Mendelian disease 
causation, with 48% of probands having an early dystonia onset, 39% having a 
positive family history for dystonia, and 18% having a generalized distribution of 
dystonic symptoms. Dystonia was the sole presenting feature in 88% of the 
probands, whereas the remainder demonstrated additional movement disorders 
and/or other neurological/extra-neurological signs.  
WES of all 225 dystonia subjects had been performed to an average on-target depth 
of 154x at the Helmholtz Center in Munich (Germany), through enrichment capture 
using the SureSelect All Exon system (Agilent Technologies) and subsequent paired-
end 100-bp sequencing on HiSeq2000/2500 instruments (Illumina) in an automated 
manner, as described previously (Zech et al., 2017; Zech et al., 2016). For WES 
summary statistics, see Table S6. Standard protocols for sequence alignment, 
variant annotation, genotype quality control, and variant visual inspection had been 
applied as detailed elsewhere (Zech et al., 2017; Zech et al., 2016). In the dominant 
model, variants were retained if they were (1) not referenced in the Exome 
Aggregation Consortium (ExAC) Browser (Lek et al., 2016) and an in-house control 
exome database (allowing the interrogation of altogether >141,000 control alleles), 
and (2) predicted to exert a loss-of-function effect (stop-gain/lost, frameshift, and 
splice-site alterations) or missense/in-frame indel alterations predicted to be among 
the 1% most deleterious aberrations in the human genome (Combined Annotation 
Dependent Depletion [CADD] score ≥20) (Kircher et al., 2014) (Figure S6A). In the 
recessive model, variants were retained if they were (1) present with a minor allele 
frequency <0.001 in the ExAC Browser and our in-house control exome database, 
and (2) predicted to exert a loss-of-function effect or missense/in-frame indel 
alterations predicted to be among the 10% most deleterious aberrations in the 
human genome (CADD score ≥10)(Kircher et al., 2014) (Figure S6A). As an 
additional supportive method for selecting the best possible candidate variants and 
genes, we obtained gene constraint metrics (probability of being loss-of-function 
intolerant (pLI) and missense Z scores) from the Exome Aggregation Consortium 
(ExAC) dataset (Lek et al., 2016) for all 216 KMT2B-target genes. ExAC-derived pLI 
scores ≥0.9 indicate that respective genes are intolerant to loss-of-function variation 
and likely relevant to haploinsufficient disease (Lek et al., 2016) ExAC-derived 
missense Z scores ≥2.0 indicate that respective genes are depleted of missense 
variants as compared with mutational expectation and thus more sensitive to this 
class of variation (Lek et al., 2016).  
The top-scoring candidate variants selected from the dominant and recessive models 
(in the KMT2B-target genes NOL4, SLC35F1 and SLC40A1) were verified by PCR 
amplification and conventional Sanger-sequencing. 
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